Research of Type 1 Diabetes

  • Diasome’s Liver Targeted Insulin

    We spoke with Robert Geho, CEO of Diasome Pharmaceuticals, Inc. — www.diasome.com — about its nanotechnology additive that delivers insulin to the liver where it can substantially improve T1D glucose control. Normal vs Injected Insulin In normal human physiology, the…

    Read More »
  • Aaron Kowalski Appointed New JDRF President/CEO

    Today, the JDRF announced the appointment of Aaron J. Kowalski, Ph.D., as the nonprofit’s President and Chief Executive Officer. A 15-year veteran of JDRF and the first person living with T1D to lead the research organization, Dr. Kowalski has a…

    Read More »
  • Oxygen Critical to Practical Islet Transplants

    We spoke with Klearchos Papas, PhD about his oxygen generator-based islet ‘tea bag’ transplant device for which the JDRF just funded a pre-clinical study (release). Dr. Papas (bio) is a professor in the Departments of Surgery, Medical Imaging, and the…

    Read More »
  • 3D Bio-Printed Bionic Pancreas

    We spoke with Michał Wszoła MD, PhD about the 3D Bio-Printed Bionic Pancreas work being done with his team and Bionic Consortium in Poland. See www.fundacjabirn.pl Problem being Addressed “Pancreatic or pancreatic islet transplantation is the only method to cure…

    Read More »
  • DRI Poseidon Trial Recruiting Children and Adults

    We spoke with Camillo Ricordi, MD, Director of the Diabetes Research Institute (DRI) about the Poseidon Trial that is actively recruiting participants. Criteria for Participation DRI is seeking 56 people – 28 adults, and 28 children – to participate in…

    Read More »
  • A New Paradigm for Type 1 Diabetes Origin

    We spoke with Ajit Shah, PhD and Peter Thompson, PhD about their research which has just been published in Cell Metabolism. This UC San Francisco study of human and mouse pancreatic tissue suggests a new origin story for type 1…

    Read More »
  • Path to Better Clinical Trials for T1D Delay/Prevention

    The Critical Path Institute (C-Path) is a catalyst in the development of new approaches including biomarkers and modeling and analysis tools to support clinical trial design and clinical outcome assessments. C-Path forms and leads consortiums that include drug developers, academics,…

    Read More »
  • BCG Vaccine Shows Promising Signals of T1D Efficacy

    We spoke with Denise Faustman, MD, Ph.D., Director of Immunobiology Massachusetts General Hospital, and Associate Professor of Medicine Harvard Medical School.  The following is a summary of the research that she and her team are working on. Early Islet Trials I…

    Read More »
  • T1D Delay/Prevention in at-risk Children

    We spoke with Pieter Rottiers, Ph.D., CEO of ActoBio Therapeutics. Genetic testing, combined with existing NIH TrialNet procedures, has shown very positive results in predicting T1D (see article). Intervention at the earliest possible time is expected to improve outcomes for…

    Read More »
  • Sernova Cell Pouch Hopes to Improve Islet Transplant Success

    Sernova is a regenerative medicine company located in London, Ontario. The corporation is led by President and CEO Dr. Philip M. Toleikis (bio) who has a strong background in implantable medical devices from twenty years in leadership roles including Angiotech…

    Read More »
  • JDRF bets that Pandion Can Help

    We spoke with Anthony Coyle, Ph.D., Co-founder and CEO of Pandion Therapeutics which is located in Cambridge Massachusetts.  This interview was stimulated by the JDRF announcement of their investment in Pandion. Paradigm Change Pandion is trying to shift the paradigm for the treatment…

    Read More »
  • Vaccine for T1 Clinical Trials

    Vaccine for T1D in Clinical Trials Soon

    INTRODUCTION Virus infections have long been considered as a possible cause of type 1 diabetes. One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started. “Epidemiological and experimental studies…

    Read More »
  • Regrowth of Human Beta Cells for T1D and T2D

    Effective Therapeutic Rate A combination of two drugs enhances the production of beta cells such that they proliferate at the highest rate ever observed in humans – a rate of 5 to 8 percent per day. “Beta cell regeneration is…

    Read More »
  • Understanding Pancreas Cell Development

    Prof. Dr. Henrik Semb who led the study explains his recent paper in Nature. Dr. Semb and his team have discovered the signals that determine the fate of immature cells in the pancreas. The research shows that they are very…

    Read More »
  • Seraxis Islet Technology Aims for Practical T1D Cure

    Islet transplants offer the hope of a permanent cure for Type 1 Diabetes.  After nearly six years in stealth mode, Seraxis has emerged as a front-runner in the race to clinical islet deployment.  Privately funded, and without any NIH or…

    Read More »
  • Dr. Paresh Dandona of Pharmacology And Toxicology at the COE

    Leveraging T2D Drugs to improve T1D Therapy

    Paresh Dandona, MD, Ph.D. (bio) has been passionate about blood sugar control since he became a Fellow in London in 1975.  He joined the faculty of the University of Buffalo School of Medicine in 1995 and has a remarkable track…

    Read More »
  • Pramlintide Reimagined and Results are Promising

    Over a decade ago, the US approval and launch of pramlintide (Symlin® AstraZeneca) brought a lot of excitement because of its therapeutic ability, when used in combination with mealtime insulin, to flatten post-meal blood glucose levels, reduce glucose excursions, and…

    Read More »
  • Could bacteria be causing diabetes?

    The relationship between gut bacteria, genetics, and T1D risk is a complicated picture, but multiple studies indicate that gut bacteria is an essential factor. TEDDY The Environmental Determinants of Diabetes in the Young (TEDDY) is on ongoing, multi-study effort that…

    Read More »
  • Metformin May Improve Vascular Health in T1D Adolescents

    Cardio vascular disease is the leading cause of mortality in people with T1D.   This relates strongly to insulin resistance and both lean and obese T1D adolescents have marked insulin resistance. Metformin is known to improve surrogate markers of insulin resistance…

    Read More »
  • Update on Inhaled Insulin

    In this period, glucose levels may fluctuate considerably.  Inhaled insulin starts working more quickly and peaks in less than one hour. Diabetes in Control reports on a recent 60-participant study that investigated the effect of multiple inhalations versus previous studies…

    Read More »
Back to top button